
    
      This is a prospective study of gut microbial markers. Patients with histologically confirmed
      advanced/unresectable or metastatic solid tumors who are planned to initiate standard of care
      ICIs or are undergoing standard of care treatment with ICIs will be approached for
      participation in the study.
    
  